HLB and its U.S. subsidiary Elevation Therapeutics said on the 22nd that they will attend the American Society of Clinical Oncology (ASCO). They plan to unveil the liver cancer drug candidate Rivoceranib. Rivoceranib, in combination with Camrelizumab from Jiangsu Hengrui Pharmaceuticals, is under review for approval by the U.S. Food and Drug Administration (FDA).
At this year's meeting, eight studies related to Rivoceranib were selected. The company plans to share research suggesting the potential to treat a variety of cancers beyond liver cancer when Rivoceranib is combined with Camrelizumab.
The company will also present on the bile duct cancer drug candidate lirafugratinib. It plans to evaluate the potential to treat not only bile duct cancer but also metastatic solid tumors. Lirafugratinib is also currently under FDA review.
The conference opens on the 29th (local time) in Chicago. Kim Dong-geon, head of Elevation Therapeutics, said, "We will inform overseas medical professionals about key clinical data and share our strategy for expanding indications."